Page 1

• • • • • • NIOX GROUP PLC ( " NIOX " or the " Company " and , together with its subsidiaries , the " Group " ) INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 Oxford , UK - 29 September 2026 : NIOX Group plc ( AIM : NIOX ) , a medical device company focused on point - of - care FeNO testing for the diagnosis , monitoring and management of asthma and COPD , today announces its unaudited interim results for the six months ended 30 June 2026 ( " H1 2026 " ) . Financial highlights Revenue of £ 24.0 million ( H1 2025 : £ 25.2 million ) . Clinical¹ revenue increased by 3 % to £ 20.6 million and was broadly unchanged on a constant currency basis ( H1 2025 : £ 20.0 million ) . Research² revenue of £ 3.4 million , reflecting the normalisation of clinical trial activity following an exceptionally strong comparative period and strategic decision to prioritise inventory within the Clinical business ( H1 2025 : £ 5.2 million ) . Adjusted EBITDA³ of £ 8.3 million ( H1 2025 : £ 9.2 million ) , reflecting lower Research revenue and well- controlled operating expenditure , despite continued investment in the US commercial organisation and product development . Gross margin at 71 % ( H1 2025 : 70 % ) , reflecting a higher mix of Clinical sales Adjusted basic earnings per share of 1.98p ( H1 2025 : 2.24p ) . Cash of £ 16.8 million at 30 June 2026 with no debt ( 30 June 2025 : £ 11.8 million , 31 December 2025 : £ 19.9 million ) , notwithstanding the payment of a £ 6.5 million dividend in June 2026. Cash at 31 August 2026 : £ 17.4 million . Revenue Gross margin Total expenditure4 Adjusted EBITDA³ Adjusted EBITDA margin Operating profit Profit before tax Profit for the period Cash at period end 1 Clinical revenue represents sales to physicians and hospitals for use in clinical practice . H1 2026 H1 2025 £ m £ m 24.0 25.2 71 % 70 % ( 8.7 ) ( 8.5 ) 8.3 9.2 34.6 % 36.5 % 5.5 5.8 6.0 5.9 5.9 5.9 16.8 11.8 2 Research revenue is from pharmaceutical companies and contract research organisations ( CROS ) for use in clinical studies . 3 Earnings before interest , tax , depreciation , amortisation and share - based payment expenses . See note 11 for reconciliation . 4 Excludes depreciation , amortisation and share - based payment expenses . See note 11 for reconciliation . Operational highlights • CE Mark and UK MHRA approval obtained for NIOX PRO® . • • • Successfully managed the transition from NIOX VERO® to NIOX PRO® , maintaining uninterrupted supply to Clinical customers with no backorders . 10 - year exclusive sensor supply agreement signed , providing long - term supply security and supporting future product development . Japan pricing increase implemented from 1 June 2026 , following the Japanese Ministry of Health reimbursement increase . • US field - based sales organisation fully deployed in March . • • • • • Master Services Agreement signed with a leading global contract research organisation , improving visibility of future Research revenues . Development of the MyNOⓇ home - use device underway . A final dividend for the financial year ended 31 December 2025 of 1.55 pence per share ( equating to a return of cash of £ 6.5 million ) was paid on 22 June 2026 . Post period end Tender offer announced today to repurchase 15,625,000 shares at 80 pence per share , returning £ 12.5 million to shareholders . If fully taken up , the Tender Offer will bring total cash returned to shareholders over the past four years in dividends and capital returns to approximately £ 60 million . Pro forma cash after tender offer ( if fully subscribed ) approximately £ 5.0 million at 30 September 2026 .